Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Endoscopy. 2010 Aug;42(8):647-51. doi: 10.1055/s-0030-1255591. Epub 2010 Jul 28.
Rectal carcinoid tumors are often found incidentally during screening colonoscopy and can be resected using various endoscopic techniques. This study aimed to compare the safety and efficacy of endoscopic submucosal dissection (ESD) with endoscopic mucosal resection (EMR) for rectal carcinoid tumors.
Between January 2003 and June 2009, 74 patients (74 lesions) underwent either EMR (n = 28) or ESD (n = 46) for rectal carcinoid tumors. The rate of endoscopic complete resection, pathological complete resection, procedure complications, and tumor recurrence were analyzed retrospectively.
The endoscopic complete resection rate was significantly higher in the ESD group (46 lesions, 100 %) compared with the EMR group (25 lesions, 89.3 %) ( P = 0.049). The pathological complete resection rate was higher in the ESD group (38 lesions, 82.6 %) compared with the EMR group (18 lesions, 64.3 %); however, this difference was borderline significant ( P = 0.067). Overall complication rate was not significantly different between the EMR group (3.6 %) and the ESD group (6.3 %). There was one case of remnant lesion in the EMR group, which was managed by ESD, and no recurrence has been detected in either the EMR or ESD groups.
This study suggests that ESD might be a feasible treatment technique for small rectal carcinoid tumors. It showed superior efficacy and comparable safety to EMR.
直肠类癌瘤通常在筛查性结肠镜检查中偶然发现,可以使用各种内镜技术进行切除。本研究旨在比较内镜黏膜下剥离术(ESD)与内镜黏膜切除术(EMR)治疗直肠类癌瘤的安全性和疗效。
2003 年 1 月至 2009 年 6 月期间,74 例(74 个病灶)患者接受 EMR(n = 28)或 ESD(n = 46)治疗直肠类癌瘤。回顾性分析内镜完全切除率、病理完全切除率、手术并发症和肿瘤复发率。
ESD 组内镜完全切除率(46 个病灶,100 %)明显高于 EMR 组(25 个病灶,89.3 %)(P = 0.049)。ESD 组病理完全切除率(38 个病灶,82.6 %)高于 EMR 组(18 个病灶,64.3 %);然而,这一差异具有边界显著性(P = 0.067)。两组总体并发症发生率无显著差异(EMR 组 3.6 %,ESD 组 6.3 %)。EMR 组有 1 例残留病灶,行 ESD 治疗,EMR 和 ESD 组均未发现复发。
本研究表明,ESD 可能是治疗小直肠类癌瘤的可行方法。它显示出优于 EMR 的疗效和可比较的安全性。